Home Stock Should you buy ChemoCentryx stock as shares spike 70% on avacopan approval?

Should you buy ChemoCentryx stock as shares spike 70% on avacopan approval?

by

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an orally administered small-molecule C5a receptor antagonist, which selectively blocks the effects of C5a through the C5a receptor. 

In May, the Arthritis Advisory Committee of the FDA issued a split 9-9 recommendation amid concerns avacopan for ANCA vasculitis showed sufficient efficacy evidence to support approval. The stock plummeted nearly 80% following the recommendation.

Despite Friday’s 70% spike in the CCXI stock price, the shares are still down nearly 44% this year.

Is it time to bet on CCXI?

From an investment perspective, ChemoCentryx is still a clinical-stage company, thereby offering little in terms of earnings. However, following Friday’s FDA approval news, investors could be looking to buy the stock amid the promising potential for growth.

Therefore, CCXI is ideal for aggressive growth investors, while value investors may opt to monitor developments around its avacopan treatment before investing. 

Nonetheless, analysts estimate its bottom line to improve by 13.60% this year ahead of an intensive marketing campaign for the newly approved drug.

Source – TradingView

Is a pullback on the horizon?

Technically, ChemoCentryx shares appear to have recently spiked, completing an upward breakout from an ascending channel formation. As a result, the stock has now rallied deep into overbought conditions, creating an opportunity for a pullback.

However, CCXI is still more than 40% down this year, leaving room for more upward movement. Therefore, investors could target extended gains at approximately $40.81, or higher at $49.35. 

On the other hand, if the stock pulls back amid reaching overbought conditions, it could find support at $26.70, or lower at $17.30.

ChemoCentryx has more ground to cover

In summary, although ChemoCentryx shares spiked 70% on Friday, the stock is yet to fully recover from the massive plunge it experienced in May.

Therefore, with the company receiving an FDA approval for avacopan for ANCA vasculitis treatment, the stock could extend the current gains even deeper into overbought conditions before finding solid resistance.

The post Should you buy ChemoCentryx stock as shares spike 70% on avacopan approval? appeared first on Invezz.

You may also like